A Study of Different Skin Care Approaches to Prevent Skin Reactions in People With Breast Cancer Receiving Radiation Therapy After Mastectomy
OPTimal Intervention for the Prevention of Radiation Dermatitis During Breast Cancer Post-Mastectomy Radiotherapy (OPTIC): A Parallel, Three-Arm, Phase II Open-Label Randomized Trial
The purpose of this study is to find out which of three standard skin care approaches works best to prevent a skin reaction called radiation dermatitis (redness, irritation, or breakdown of the skin) in people receiving radiation therapy after mastectomy.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Atif Khan, MD
- 전화번호: 848-225-6334
- 이메일: khana7@mskcc.org
연구 연락처 백업
- 이름: Isabelle Choi, MD
- 전화번호: 646-449-1997
- 이메일: choij3@mskcc.org
연구 장소
-
-
New Jersey
-
Basking Ridge, New Jersey, 미국, 07920
- 모병
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
-
연락하다:
- Isabelle Choi, MD
- 전화번호: 646-449-1997
-
Middletown, New Jersey, 미국, 07748
- 모병
- Memorial Sloan Kettering Monmouth (All Protocol Activities)
-
연락하다:
- Isabelle Choi, MD
- 전화번호: 646-449-1997
-
Montvale, New Jersey, 미국, 07645
- 모병
- Memorial Sloan Kettering Bergen (All Protocol Activities)
-
연락하다:
- Isabelle Choi, MD
- 전화번호: 646-449-1997
-
-
New York
-
Commack, New York, 미국, 11725
- 모병
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities )
-
연락하다:
- Isabelle Choi, MD
- 전화번호: 646-449-1997
-
Harrison, New York, 미국, 10604
- 모병
- Memorial Sloan Kettering Westchester (All Protocol Activities)
-
연락하다:
- Isabelle Choi, MD
- 전화번호: 646-449-1997
-
New York, New York, 미국, 10065
- 모병
- Memorial Sloan Kettering Cancer Center (All Protocol Activites)
-
연락하다:
- Isabelle Choi, MD
- 전화번호: 646-449-1997
-
Rockville Centre, New York, 미국, 11553
- 모병
- Memorial Sloan Kettering Nassau (All protocol activities)
-
연락하다:
- Isabelle Choi, MD
- 전화번호: 646-449-1997
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients must have pathologically confirmed breast cancer.
- Patients will have an assigned sex of female at birth.
- Patients will have undergone mastectomy without breast reconstruction surgery or with immediate reconstruction using one or more of an expander, implant, or flap-based approach.
- Patients will have pathologic stage T1-3 N0-1 M0 disease with indication for comprehensive post-mastectomy radiotherapy to the ipsilateral chest wall and regional lymph node basins (axilla, SCV, IMN).
- Patient/LAR willing to sign and date consent form
- Age ≥ 18
- ECOG Performance Status of ≤ 2
Exclusion Criteria:
-
Patients with indication for escalated skin dose (dermal invasion, skin involvement, positive surgical margin).
-
Patients planned to receive a scar or chest wall, or other boost.
-
Patients planned to receive post-mastectomy radiotherapy using a hypofractionated regimen (ie., >2.0 Gy per fraction).
-
Patients who have a diagnosis of connective tissue disorder or collagen vascular disorder.
-
Patients who have an active rash in the cervical or thoracic region.
-
Patients taking systemic steroids >10 mg/day.
-
Patients on active antimicrobial treatment at the time of study enrollment.
-
Patients with a prior history of organ or bone marrow transplant.
-
Patients who are pregnant or nursing
-
Prior Treatment:
- Patients with prior history of radiotherapy to the neck, thorax or abdomen.
- Resolution of all toxicities of prior therapy or surgical procedures to baseline or Grade 1 (except for hypothyroidism requiring medication, which must have resolved to Grade ≤2, alopecia, and other toxicities considered clinically nonsignificant and/or stable on supportive therapy as determined by the investigator).
-
Comorbid conditions:
o Active infection requiring parenteral antibiotic(s)
-
Concomitant Medications:
o Concurrent systemic therapy during the course are not allowed, including cytotoxic chemotherapy, immunotherapy, and targeted therapy. Last dose of these agents must be delivered at least 2 weeks prior to start of radiotherapy and not to be restarted until at least 2 weeks following completion of radiotherapy. Endocrine therapy, pembrolizumab, Herceptin, Perjeta, and Kadcyla are allowed. Concurrent oral steroid medications are not allowed.
-
Allergies:
- History of allergic reaction to the study agent(s), compounds of similar chemical or biologic composition to the study agent (s) (or any of its excipients).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Arm 1: Mometasone furoate
An ARD prevention strategy that has demonstrated the ability to reduce significant radiation dermatitis during breast radiotherapy is the topical application of corticosteroid creams, including mometasone and betametasone |
Mometasone Furoate 1% Cream is a topical corticosteroid cream |
|
실험적: Arm 2: Mepitel Film
The use of barrier films such as Mepitel Film, Hydrofilm, and StrataXRT, has also been demonstrated to be effective in reducing the risk of clinically significant ARD. |
Mepitel Film is a transparent film with a contact layer with silicone adhesion. |
|
실험적: Arm 3: Bacterial decolonization
Bacterial decolonization (BD) is a intervention that has been studied as an ARD prevention measure. |
Bacterial decolonization (BD) regimen involves a 5 day regimen of twice-daily intranasal mupirocin and chlorhexidine body cleansing Bacterial decolonization (BD) regimen involves a 5 day regimen of twice-daily intranasal mupirocin and chlorhexidine body cleansing |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Rate of acute radiation dermatitis with most desquamation (ARD-MD)
기간: 12 months
|
To evaluate the rate of acute radiation dermatitis with moist desquamation (ARD-MD) using three acute radiation dermatitis (ARD) prevention strategies compared with historical rates using standard of care strategies in patients receiving post-mastectomy radiotherapy (PMRT). |
12 months
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Isabelle Choi, MD, Memorial Sloan Kettering Cancer Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 26-356
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .